跳至主要内容
临床试验/NCT03057379
NCT03057379已完成不适用

State Immunization Information Systems to Improve HPV Vaccination Rates

University of California, Los Angeles2 个研究点 分布在 1 个国家目标入组 30,616 人开始时间: 2017年2月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30,616
试验地点
2
主要终点
Completion of the HPV vaccine series (receipt and documentation of final dose of vaccine series within immunization registry)

研究概览

简要总结

The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness and sustainability of utilizing statewide Immunization Information Systems (IIS) to conduct centralized reminder/recall (R/R) to improve Human Papiloma Virus (HPV) vaccination rates among adolescents ages 11-17.

详细描述

The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness and sustainability of utilizing statewide Immunization Information Systems (IIS) to conduct centralized reminder/recall (R/R) to improve HPV vaccination rates among adolescents ages 11-17. The investigators will extend previous research on effectiveness of centralized R/R to a new population--adolescents due for HPV vaccine-- and test the use of centralized R/R as a cancer-prevention strategy. Investigators will assess the effect of centralized R/R in two states--one with and one without mandated reporting of vaccinations to IISs, and disseminate IIS R/R to other states. Investigators will implement, evaluate (using the RE-AIM framework 31-36), and disseminate a collaborative, IIS-based centralized HPV vaccine R/R model in which partnerships of public health systems and primary care practices in two states (NY, CO) collaborate to remind parents about HPV vaccination.

Specific Aims and hypotheses:

Aim #1: Adapt IIS messages and delivery systems (e.g., algorithms) previously developed for centralized R/R for other vaccines to fit HPV vaccine IIS R/R.

Aim #2: Assess the impact and cost-effectiveness of centralized IIS-based (IIS-C) autodialer (phone) R/R in increasing vaccine rates [initial dose (HPV#1) and a complete series (HPV#3)] among teens.

Conduct a pragmatic trial, to assess the impact and cost effectiveness of centralized IIS-based (IIS-C) autodialer (phone) R/R in increasing initiation and completion rates for the HPV vaccine series in adolescents ages 11-17 years. The investigators will use a within-practice design, randomizing patients within randomly selected primary care practices to IIS-C R/R (1, 2, or 3 reminders per dose) compared to usual care (0 reminders from this study). The investigators will apply the RE-AIM framework to evaluate the reach, effectiveness/cost effectiveness, adoption, and implementation of IIS-C R/R.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Double (Care Provider, Outcomes Assessor)

入排标准

年龄范围
11 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 11 through 17 years of age
  • patient of a participating practice (practices randomly selected)
  • is either due for an HPV dose at baseline, or
  • has initiated but not yet completed the HPV series at baseline

排除标准

  • has completed the HPV vaccination series

结局指标

主要结局

Completion of the HPV vaccine series (receipt and documentation of final dose of vaccine series within immunization registry)

时间窗: 5 months from first reminder received for last dose

Did those eligible to complete the HPV vaccine series within the time frame of the study do so? The investigators are allowing up to 5 months after the first recall notice of the last dose (could be dose 2 or dose 3, depending on the age at which they received their first dose) for adolescents to complete their vaccination series. After that time frame, the investigators will not attribute vaccination to the recall. Receipt will be documented by providers within the state immunization registry via EMR direct transfer or manual entry.

Initiation of the HPV vaccine series (receipt and documentation of initial dose of vaccine series within immunization registry)

时间窗: 5 months from initial recall notices for the first dose

Did the adolescent initiate the HPV vaccine series? The investigators are allowing up to 5 months after the initial recall notice for the adolescent to make an appointment and receive their dose. After that time frame, the investigators will not attribute vaccination to the recall. Receipt will be documented by providers within the state immunization registry via electronic medical record (EMR) direct transfer or manual entry.

次要结局

  • Differences between arms - initiation(5 months)
  • Differences between arms - completion(20 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Peter G Szilagyi, MD MPH

Professor of Pediatrics

University of California, Los Angeles

研究点 (2)

Loading locations...

相似试验